Emoxibel - Instructions For Use, Price, Reviews, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Emoxibel

Emoxibel: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. Drug interactions
12. 12. Analogs
13. 13. Terms and conditions of storage
14. 14. Terms of dispensing from pharmacies
15. 15. Reviews
16. 16. Price in pharmacies

Latin name: Emoxibel

ATX code: S.01. XA

Active ingredient: Methylethylpyridinol (Methylaethylpiridinolum)

Manufacturer: BELMEDPREPARATY, RUE (Republic of Belarus)

Description and photo update: 2018-25-10

Prices in pharmacies: from 83 rubles.

Buy

Emoxibel is an antioxidant drug.

Release form and composition

Dosage forms of Emoxibel:

• solution for infusion: colorless, transparent (in glass bottles, 100 ml, in a cardboard box 1 bottle);
• solution for intravenous (i / v) and intramuscular (i / m) administration: slightly colored or colorless, transparent (in vials of 10 ml, in ampoules of 5 ml, in blister packs of 5 ampoules; in a cardboard box 1 or 2 packaging or 1 bottle);
• eye drops: with a yellow tint or colorless, transparent (in bottles of 5 ml, in a cardboard box 1 bottle);
• solution for injections: colorless, transparent (in 1 ml ampoules, in blister packs of 5 ampoules, in a cardboard box 10 ampoules or 1 or 2 packs with an ampoule scarifier included).

Composition of 1 ml solution for infusion Emoxibel:

• active substance: methylethylpyridinol hydrochloride (emoxipin) - 0.005 g;
• auxiliary components: water for injection, sodium chloride.

Composition of 1 ml solution for intravenous and intramuscular administration of Emoxibel:

• active substance: methylethylpyridinol hydrochloride (emoxypin) - 0.03 g;
• auxiliary components: water for injection, sodium hydrogen phosphate dodecahydrate, sodium sulfite.

Composition of 1 ml of Emoxibel eye drops:

• active substance: methylethylpyridinol hydrochloride (emoxipin) - 0.01 g;
• auxiliary components: water for injection - up to 1 ml, sodium hydrogen phosphate dodecahydrate - 0.007 5 g; potassium dihydrogen phosphate - 0.006 2 g; sodium benzoate - 0.002 g; sodium sulfite - 0.003 g

Composition of 1 ml solution for injection Emoxibel:

• active substance: methylethylpyridinol hydrochloride (emoxipin) - 0.01 g;
• auxiliary components: water for injection - up to 1 ml, hydrochloric acid solution (0.1 M) - 0.02 ml.

Pharmacological properties

Pharmacodynamics

Thanks to the active substance included in the composition, Emoxibel performs the following actions:

• has a beneficial effect on the blood coagulation system: it lengthens the blood coagulation time, reduces the total coagulation index, inhibits platelet aggregation;
• increases the resistance of erythrocytes to hemolysis and mechanical injury, stabilizes the cell membranes of blood vessels and erythrocytes;
• improves microcirculation;
• increases the activity of antioxidant enzymes, effectively inhibits free-radical oxidation of lipids of biomembranes;
• has an antitoxic and angioprotective effect, stabilizes cytochrome P ₄₅₀;
• optimizes bioenergetic processes in extreme situations, accompanied by hypoxia and increased lipid peroxidation;
• increases the resistance of the brain to ischemia and hypoxia;
• with ischemic and hemorrhagic disorders of cerebral circulation, it improves mnestic functions, facilitates the restoration of the integrative activity of the brain, helps to correct autonomic dysfunctions;
• reduces the synthesis of triglycerides, has hypolipidemic properties;
• reduces ischemic damage to the myocardium, dilates coronary vessels;
• in case of myocardial infarction, it helps to normalize myocardial metabolism, accelerates reparative processes, and limits the size of the necrosis focus;
• by reducing the incidence of acute heart failure, it has a beneficial effect on the clinical course of myocardial infarction;
• in case of insufficient blood circulation, it provides regulation of the redox system.

Pharmacokinetics

Characteristics of methylethylpyridinol hydrochloride (emoxipin):

• absorption: with intravenous administration, it has a low half-elimination period (T _½ is 18 minutes, which indicates a high rate of elimination from the blood); the value of the elimination constant - 0.041 min; total clearance of Cl - 214.8 ml per 1 min;
• distribution: apparent volume of distribution - 5.2 liters; quickly penetrates the organs and tissues of the human body, where it is subsequently deposited and metabolized;
• metabolism: has 5 metabolites, represented by conjugated and dealkylated products of its transformation; metabolites are excreted by the kidneys; in the liver, 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in significant quantities;
• excretion: pathological conditions reduce the rate of its excretion, which increases its bioavailability, and also increases the time it is in the bloodstream (may be associated with its return from the depot, including from the ischemic myocardium).

The pharmacokinetics of Emoxibel under pathological conditions changes (for example, with coronary occlusion).

Indications for use

Solution for infusion, solution for intravenous and intramuscular administration

• postoperative period in patients with traumatic brain injury, operated on for intracerebral, subdural and epidural hematomas, combined with brain contusions, traumatic brain injury with cerebral contusions, chronic cerebrovascular accident, transient cerebrovascular accident, hemorrhagic stroke, and ischemic stroke in the basin of the internal carotid artery and in the vertebrobasilar system (use in neurosurgery and neurology);
• unstable angina pectoris, prevention of reperfusion syndrome, acute myocardial infarction (use in cardiology).

Eye drops

• complicated myopia;
• degenerative diseases of the cornea;
• burn, inflammation and trauma of the cornea;
• intraocular and subconjunctival hemorrhages of various origins;
• protection of the cornea (when wearing contact lenses).

Injection

• burns, trauma, degenerative diseases of the cornea;
• detachment of the vascular retina of the eye with glaucoma in the postoperative period;
• dry form of angiosclerotic macular degeneration;
• complicated myopathy;
• chorioretinal dystrophy (central and peripheral);
• angioretinopathy, including diabetic;
• intraocular and subconjunctival hemorrhages of various origins;
• thrombosis of the central retinal vein and its branches;
• prevention and therapy of eye lesions with high-intensity light (laser radiation during laser coagulation, sunlight).

Contraindications

Absolute:

• age under 18;
• pregnancy (except solution for injection);
• lactation period (except for solution for injection);
• individual intolerance to the components of the drug.

Relative (diseases / conditions in the presence of which the appointment of Emoxibel requires caution):

• solution for intravenous and intramuscular administration: the presence of symptoms of severe bleeding, surgical operations, impaired hemostasis;
• solution for injection: pregnancy, lactation.

Instructions for the use of Emoxibel: method and dosage

Solution for infusion

Emoxibel is administered under the control of the functional state of the blood coagulation and anticoagulant systems, blood pressure intravenously, intramuscularly.

Dosing regimen:

• neurology, neurosurgery: the daily dose is 0.005–0.01 g per 1 kg of body weight for 10–12 days, injected intravenously at a rate of 20–30 drops per minute. Then the patient is transferred to intramuscular injection of 2-10 ml (0.06-0.3 g) of a solution with a concentration of 0.03 g per 1 ml 2-3 times a day for 10-30 days;
• cardiology: initial dose - 120-180 ml (0.6-0.9 g) 1-3 times a day intravenous drip at a rate of 20-40 drops per minute for 5-15 days (depending on the course of the pathology). Then the patient is transferred to intramuscular injection of 2-10 ml (0.06-0.3 g) of a solution with a concentration of 0.03 g per 1 ml 2-3 times a day for 10-30 days.

Solution for i / v and i / m administration

Emoxibel is administered intravenously or intramuscularly. Before intravenous administration, the solution is diluted in 200 ml of dextrose solution 5% or sodium chloride 0.9%.

The dosage of the drug and the duration of therapy are set individually.

Dosing regimen:

• neurology, neurosurgery: intravenous drip of 0.01 g per 1 kg of body weight per day at a rate of 20-30 drops per minute for 10-12 days, then the patient is transferred to intramuscular injection at 0.06-0, 3 g 2-3 times a day for 20 days;
• cardiology: intravenous drip, 0.6-0.9 g 1-3 times a day at a rate of 20-40 drops per minute for 5-15 days, with further transfer of the patient to intramuscular injection 0.06-0, 3 g of the drug 2-3 times a day for 10-30 days.

Eye drops

Emoxibel is instilled into the conjunctival sac.

The daily dose is 1-2 drops 2-3 times a day.

Immediately before use, remove the aluminum cap from the bottle, remove the rubber stopper and close the bottle with a dropper cap previously released from the package. Next, the cap is removed from the dropper cap, the bottle is turned over, and the required amount of the product is instilled. After use, the bottle is returned to an upright position, a cap is put on the dropper cap.

The duration of therapy is determined by the doctor depending on the course of the pathology. It usually varies from 3 to 30 days. In the presence of indications and good tolerance of Emoxibel, the duration of treatment can be increased to 6 months. It is allowed to conduct repeated courses of therapy 2-3 times a year.

Injection

Emoxibel is administered parabulbarly, subconjunctivally or retrobulbarly, once a day or every other day.

Parabulbarly inject 0.005-0.01 g of 1% solution (0.5-1 ml), subconjunctivally - 0.002-0.005 g of 1% solution (0.2-0.5 ml), for 10-30 days (possibly repetition of the course of treatment 2-3 times a year). Retrobulbar is administered at 0.005-0.01 g of 1% solution (0.5-1 ml) 1 time per day for 10-15 days.

When carrying out laser coagulation (to protect the retina), 1% solution is injected retrobulbar or parabulbar at 0.005-0.01 g (0.5-1 ml) 24 hours and 1 hour before coagulation, then the same dose is administered once a day for for 2-10 days.

Side effects

Solution for infusion, solution for intravenous and intramuscular administration

• allergic reactions;
• redness and itching of the skin;
• epigastric discomfort, nausea;
• pain in the region of the heart;
• headache;
• drowsiness or agitation, increased blood pressure;
• burning sensation along the vein (with intravenous injection).

Eye drops

• short-term conjunctival hyperemia;
• itchy eye;
• burning sensation;
• local allergic reactions (rare).

Injection

• nervous system: drowsiness, short-term agitation;
• cardiovascular system: increased blood pressure;
• allergic reactions: peeling of the skin, itching, erythema, edema, flushing of the skin;
• others: reactions at the injection site (compaction of paraorbital tissues, hyperemia, itching, burning, pain).

Overdose

The main symptoms: short-term increase in blood pressure, increased side effects of the drug.

Therapy: symptomatic treatment.

special instructions

Emoxibel therapy is carried out under constant monitoring of blood clotting and blood pressure.

The solution for infusion should not be mixed with other drugs.

Before instillation of eye drops, soft contact lenses should be removed. After 20 minutes (not earlier), the lenses can be put on again. In cases of combined therapy with other eye drops, Emoxibel is instilled last, 15 minutes (not earlier) after the previous drug is completely absorbed.

Influence on the ability to drive vehicles and complex mechanisms

At the beginning of the use of the solution for infusion, as well as patients who notice drowsiness or a decrease in blood pressure after using the solution for intravenous and intramuscular administration or solution for injection, you should refrain from driving and conducting potentially hazardous activities.

Application during pregnancy and lactation

Solution for infusion, solution for intravenous and intramuscular injection and eye drops are contraindicated for use during pregnancy and lactation.

Solution for injection Emoxibel is prescribed with caution during pregnancy and lactation.

Pediatric use

According to the instructions, Emoxibel is contraindicated in children under the age of 18.

Drug interactions

The antioxidant effect of the drug potentiates α-tocopherol acetate.

Analogs

Emoxibel's analogs are: Emoxipin, Methylethylpyridinol, Emoxy-optic, Cardioxipin.

Terms and conditions of storage

Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Emoxibel

There are few reviews about Emoxibel, indicating the effectiveness of the drug.

Price for Emoxibel in pharmacies

The approximate price of Emoxibel (solution for injection, 10 ampoules per package) is 65 rubles.

Emoxibel: prices in online pharmacies

Drug name Price Pharmacy

Emoxibel 10 mg / ml solution for intraocular administration 1 ml 10 pcs. 83 rbl. Buy

Emoxibel 1% eye drops 5 ml 1 pc. RUB 98 Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!